Running away or righting the way: is psilocybin a viable psychiatric treatment?
[Due to the Controlled Substances Act of 1970] … absence of clinical evidence soon became a compounded issue. When there’s no research, attention tends to wane. Not only do clinical trials stop, but meta-analyses and trial reviews cease too. As a result, physician awareness and interest in exploring novel psychedelic therapies dwindles. “But when you go back and look, [several trials] found that, in fact, there was a robust effect of psilocybin over control treatment at the first follow-up and it persisted for at least 6 months.” That evidence alone is strong enough to warrant continued studies on psychedelics, he said. -Mike Bogenschutz, MD, professor of psychiatry at New York University School of Medicine.
“You have this mountain of studies until about 1970, and then it stops. All human studies stopped, so there were just ongoing animal studies that were trying to understand their abuse liability,” said Charles L. Raison, MD, professor in the School of Human Ecology at the University of Wisconsin-Madison. “There was a hiatus of 26 or 27 years where research was just killed, and when it started again there were significant difficulties and significant pressure. It was really a challenge.” Had psychedelics been available to study in the 1980s when modern pharmacology started to take off, people would have studied it, Raison said. Physicians and scientists would have been able to push harder to pursue them for an indication. “I’m almost certain that we’d be in a totally different world,” he said.
Original Article (MD Mag):
Running Away or Righting The Way: Is Psilocybin a Viable Psychiatric Treatment?
Artwork Fair Use: Beyond My Ken